therapy of type 2 diabetes mellitus: update
DESCRIPTION
Therapy of Type 2 Diabetes Mellitus: UPDATE. Glycemic Goals in the Care of Patients with Type 2 Diabetes- 2013 ADA and AACE Guidelines: Room For Improvement (Be HAPPY/ Avoid Burnout, While Caring for Patients with DM). Stan Schwartz MD, FACP, FACE Affiliate, Main Line Health System - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/1.jpg)
Therapy of Type 2 Diabetes Mellitus: UPDATE
Glycemic Goals in the Care of Patients with Type Glycemic Goals in the Care of Patients with Type 2 Diabetes- 2013 ADA and AACE Guidelines:2 Diabetes- 2013 ADA and AACE Guidelines:
Room For Improvement Room For Improvement
(Be HAPPY/ Avoid Burnout, While Caring for Patients with DM)(Be HAPPY/ Avoid Burnout, While Caring for Patients with DM)
Stan Schwartz MD, FACP, FACEAffiliate, Main Line Health System
Clinical Associate Professor of Medicine, Emeritus, U of Pa.
![Page 2: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/2.jpg)
Early Treatment Decreases Micro and Macro Vascular
RISK
![Page 3: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/3.jpg)
Impact of Intensive Therapy in Type 2 Diabetes Summary of Major Clinical Trials:
BUT Subset Evaluations Show Reduced CV Outcomes if shorter duration of DM, without significant pre-existing complications
Study Microvascular Macrovascular Mortality
UGDP ↔ ↔ ↔UKPDS ↓ ↓ ↔ ↓ ↔ ↓
DCCT/EDIC* ↓ ↓ ↔ ↓ ↔ ↔ACCORD ↓ ↔ ↑(unadj.), ↔ (adj.)
ADVANCE ↓ ↔ ↔VADT ↔ ↔ ↔
Initial Trial Long Term Follow-up
Meinert CL. Diabetes. 1970;19(suppl):789-830.
Goldner MG. JAMA. 1971;218(9):1400-1410.UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865. Holman RR. N Engl J Med. 2008;359(15):1577-1589.DCCT Research Group. N Engl J Med. 1993;329;977-986.Nathan DM, et al. N Engl J Med. 2005;353:2643-2653.
Gerstein HC, et al. N Engl J Med. 2008;358:2545-2559.Patel A, et al. N Engl J Med. 2008;358:2560-2572.Duckworth W, et al. N Engl J Med. 2009;360.
*T1DM study.
↑↑- - likely due to likely due to hypoglycemia hypoglycemia and weight gainand weight gain
![Page 4: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/4.jpg)
Intensive treatment/standard treatment
Weight ofstudy size
Odds ratio(95% CI)
Odds ratio(95% CI)
Participants Events
UKPDS 3071/1549 426/259 8.6% 0.75 (0.54–1.04)
PROactive* 2605/2633 164/202 20.2% 0.81 (0.65–1.00)
ADVANCE 5571/5569 310/337 36.5% 0.92 (0.78–1.07)
VADT 892/899 77/90 9.0% 0.85 (0.62–1.17)
ACCORD 5128/5123 205/248 25.7% 0.82 (0.68–0.99)
Overall 17267/15773 1182/1136 100% 0.85 (0.77–0.93)
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8Intensive treatment better Standard treatment better
*Included on-fatal MI and death from all-cardiac mortality
Probability of events of CAD with intensive glucose-lowering vs. standard treatment
2.0
Intensive treatment/standard treatment
Weight ofstudy size
Odds ratio(95% CI)
Odds ratio(95% CI)
Participants Events
UKPDS 3071/1549 221/141 21.8% 0.78 (0.62–0.98)
PROactive* 2605/2633 119/144 18.0% 0.83 (0.64–1.06)
ADVANCE 5571/5569 153/156 21.9% 0.98 (0.78–1. 23)
VADT 892/899 64/78 9.4% 0.81 (0.58–1.15)
ACCORD 5128/5123 186/235 28.9% 0.78 (0.64–0.95)
Overall 17267/15773 743/754 100% 0.83 (0.75–0.93)
Intensive treatment better Standard treatment better
Probability of events of non-fatal MI with intensive glucose-lowering vs. standard treatment
www.thelancet.com. Vol 373 May 23, 2009.
Lancet Meta-analysis
0.4 0.6 0.8 1.0 1.2 1.4 1.61.8 2.0
0.9% Dec. HbA1c,17% Dec. non-fatal MI,
15% Dec. CV events of CAD
![Page 5: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/5.jpg)
![Page 6: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/6.jpg)
![Page 7: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/7.jpg)
![Page 8: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/8.jpg)
![Page 9: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/9.jpg)
![Page 10: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/10.jpg)
Hypoglycemia Outcomes VADT, ACCORD, ADVANCE
![Page 11: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/11.jpg)
Consequences of Hypoglycemia• Prolonged QT- intervals- Diabetologia 52:42,2009
–Can be of pronged duration IJCP Sup 129, 7/02
–Greater with higher catecholamine levels Europace 10,860
• Associated with Angina Diabetes Care 26, 1485, 2003 / Ischemic EKG changes Porcellati, ADA2010
• Associated with Arrhythmias• Associated with Sudden Death Endocrine Practice 16,¾ 2010
• Increased Variabilty- explains highest mortality in intensive group had highest HgA1c in
ACCORD ( increases inflammation, ICU mortality Hirsch ADA2010)
![Page 12: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/12.jpg)
RISK OF TOO TIGHT CONTROL OF HYPERGLYCEMIA IN HOSPITALS
VALUE OF CONTROLLING HYPERGLYCEMIA IN HOSPITAL
![Page 13: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/13.jpg)
So given epidemiologic data, CV risk/glucose data and now ADVANCE, VADT, ACCORD, implications of weight gain and
hypogycemia, what are/ should be goals (SSS)1. ADA- stayed at <7.0 AACE – stayed at < 6.5
Lowest possible as long as no undue risk of hypoglycemia and visceral weight gain
2. ADA and AACE- a. Start early in DM -
implications for prevention- lifestyle and drug therapy of metabolic syndrome and IGT
b. do not aim for aggressive control in those with significant pre-existing CV disease
Disagree- lowest possible without hypoglycemia, weight gain3.Modify goals for ‘elderly’
Disagree- lowest possible without hypoglycemia, weight gain
![Page 14: Therapy of Type 2 Diabetes Mellitus: UPDATE](https://reader036.vdocuments.net/reader036/viewer/2022062422/568134ac550346895d9bc042/html5/thumbnails/14.jpg)
Greater Survival in Elderly (>75yo) with lower HgA1c
EASD , 9/2010
So…WHY NOT BE AGGRESSIVE IN GLYCEMIC CONTROL
IF… NOT USING HYPOGLYCEMIC AGENTS